115 related articles for article (PubMed ID: 29352718)
1. Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based Study.
Fluge Ø; Mannsåker B; Torp A; Mjaaland I; Helgeland L; Klos J; Mella O; Berentsen S; Meyer P
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):125-135.e3. PubMed ID: 29352718
[TBL] [Abstract][Full Text] [Related]
2. The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era.
Cassidy RJ; Jegadeesh N; Switchenko J; Danish H; Esiashvili N; Flowers CR; Khan MK
Leuk Lymphoma; 2016 Aug; 57(8):1876-82. PubMed ID: 26759182
[TBL] [Abstract][Full Text] [Related]
3. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
[TBL] [Abstract][Full Text] [Related]
4. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
[TBL] [Abstract][Full Text] [Related]
5. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation.
Jegadeesh N; Rajpara R; Esiashvili N; Shi Z; Liu Y; Okwan-Duodu D; Flowers CR; Khan MK
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):107-12. PubMed ID: 25863758
[TBL] [Abstract][Full Text] [Related]
6. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
[No Abstract] [Full Text] [Related]
7. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
8. A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy.
Hwang HS; Yoon DH; Suh C; Huh J
Ann Hematol; 2016 Aug; 95(8):1249-58. PubMed ID: 27167532
[TBL] [Abstract][Full Text] [Related]
9. Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era.
Sert F; Kamer S; Saydam G; Anacak Y
J Cancer Res Ther; 2018; 14(6):1397-1402. PubMed ID: 30488862
[TBL] [Abstract][Full Text] [Related]
10. Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the Rituximab era: a SEER database analysis.
Liu PP; Wang KF; Jin JT; Bi XW; Sun P; Wang Y; Yang H; Li ZM; Jiang WQ; Xia Y
Cancer Med; 2018 May; 7(5):1845-1851. PubMed ID: 29624913
[TBL] [Abstract][Full Text] [Related]
11. Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy?
Vargo JA; Gill BS; Balasubramani GK; Beriwal S
J Clin Oncol; 2015 Nov; 33(32):3710-7. PubMed ID: 26261253
[TBL] [Abstract][Full Text] [Related]
12. Significance of bulky mass and residual tumor-Treated with or without consolidative radiotherapy-To the risk of relapse in DLBCL patients.
Tokola S; Kuitunen H; Turpeenniemi-Hujanen T; Kuittinen O
Cancer Med; 2020 Mar; 9(6):1966-1977. PubMed ID: 31967739
[TBL] [Abstract][Full Text] [Related]
13. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
14. Changes in treatment patterns and impact of radiotherapy for early stage diffuse large B cell lymphoma after Rituximab: A population-based analysis.
Haque W; Dabaja B; Tann A; Khan M; Szeja S; Butler EB; Teh BS
Radiother Oncol; 2016 Jul; 120(1):150-5. PubMed ID: 27373911
[TBL] [Abstract][Full Text] [Related]
15. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
16. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C
Am J Hematol; 2013 Dec; 88(12):1062-7. PubMed ID: 23940056
[TBL] [Abstract][Full Text] [Related]
17. A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry.
Gang AO; Pedersen M; d'Amore F; Pedersen LM; Jensen BA; Jensen P; Møller MB; Mourits-Andersen HT; Pedersen RS; Klausen TW; de N Brown P
Leuk Lymphoma; 2015; 56(9):2556-62. PubMed ID: 25629994
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
Rezazadeh A; Szabo A; Khurana A; Inwards DJ; Lunning MA; Bartlett NL; Caimi PF; Rodgers TD; Barr PM; Chowdhury SM; Epperla N; Mendries H; Hill BT; Oh TS; Karmali R; Chang JE; Goyal G; Parsons BM; Isaac KM; Portell CA; Monahan K; Siker M; King DM; Fenske TS
Haematologica; 2024 May; 109(5):1439-1444. PubMed ID: 37855051
[TBL] [Abstract][Full Text] [Related]
19. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
20. Older patients with early-stage diffuse large B-cell lymphoma: the role of consolidation radiotherapy after chemoimmunotherapy.
Parikh RR; Yahalom J
Leuk Lymphoma; 2017 Mar; 58(3):614-622. PubMed ID: 27685446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
